Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stew Kroll

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerMitesh J Borad, Shantan G Reddy, Nathan Bahary, et al.
Critical Care Medicine|March 7, 2018
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin IIJames A Tumlin, Raghavan Murugan, Adam M Deane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
The New England Journal of Medicine|May 23, 2017
Angiotensin II for the Treatment of Vasodilatory ShockAshish Khanna, Shane W English, Xueyuan S Wang, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerMitesh J Borad, Shantan G Reddy, Nathan Bahary, et al.
Critical Care Medicine|March 7, 2018
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin IIJames A Tumlin, Raghavan Murugan, Adam M Deane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
The New England Journal of Medicine|May 23, 2017
Angiotensin II for the Treatment of Vasodilatory ShockAshish Khanna, Shane W English, Xueyuan S Wang, et al.
Pageof 2